Consider pulmonary hypertension as a possible diagnosis in patients with unexplained breathlessness and in high risk groups such as patients with systemic sclerosis and past history of pulmonary embolism.
Pulmonary hypertension (PH) is a challenging condition to diagnose, accurately classify and treat. There is often a delay from the onset of symptoms to diagnosis of up to three years. 1, 2 The diagnostic process currently requires invasive investigations. Treatments are now effective, but often complex. Until the advent of transplantation in the 1980s there was no specific treatment for PH. The last two decades have seen the development of novel therapies which improve symptoms and survival of patients with PH.
PH is defined as a mean pulmonary artery pressure of 25 mmHg or above at rest or 30 mmHg or above on exercise. 1 The World Health Organization recently reclassified PH and identified five major groups (Table 1) , demonstrating the importance of identifying the cause of PH in deciding on treatment. Patients with chronic thromboembolic pulmonary hypertension (CTEPH) can be cured by surgery. Those with pulmonary arterial hypertension (PAH) ( Table 2 ) can be improved with selective pulmonary arterial vasodilators, but these drugs can precipitate pulmonary oedema in patients with pulmonary venous hypertension.
Epidemiology
PAH and CTEPH have an estimated prevalence of 30-50 cases per million. Idiopathic pulmonary hypertension (IPH), a form of PAH previously called primary pulmonary hypertension, is a severe, progressive disease with an incidence of 1-2 cases per million per year and three times more common in women. 2 Without targeted pulmonary vascular therapy, it has a median survival of 2.8 years from diagnosis.
Making the diagnosis
The non-specific nature of the symptoms and the subtle nature of the signs of pulmonary vascular disease often delay diagnosis. Making a diagnosis therefore requires an awareness of the possibility of PH and recognition of the prevalence of pulmonary vascular disease in patients with associated conditions such as systemic sclerosis (10-20%), 3 sickle cell disease (20%), HIV infection (0.5-2%), portal hypertension (1-2%), pulmonary embolic disease and congenital heart disease.
Clinical features
The cardinal symptom of PH is breathlessness because the right heart is unable to generate a sufficient increase in cardiac output on exercise. Initially, this may be mild but it is progressive and later may be accompanied by chest pains (similar to angina) and syncope, often on exercise. Syncope usually reflects a low cardiac output and indicates severe disease. As right heart failure develops, abdominal distension, general fatigue and ankle swelling may appear -ankle swelling occurs only late in the natural history of the disease.
Signs on examination may initially be few but are more readily seen with disease progression (and after the diagnosis is made) ( Table 3) .
Investigations
Key basic investigations include an ECG and/or chest X-ray (CXR) which are abnormal in approximately 80% of patients. Pulmonary function tests may suggest an alternative diagnosis. The most common investigation suggesting PH is a trans-thoracic echocardiogram. This allows estimation of the systolic pulmonary artery pressure from the tricuspid regurgitant jet using Doppler echocardiography. Dilated right-sided chambers or paradoxical septal motion may also be observed, reflecting high right-sided pressures. Echocardiography may also help to identify the cause (valvular heart disease, left ventricular dysfunction, intracardiac shunts). If significant PH is suspected, the patient should be referred to a specialist centre for further investigation and assessment. Patients with PH due to leftsided heart problems and underlying respiratory disease are most effectively treated by addressing the underlying cause (Table 1) .
Further assessment
Following referral, invasive investigation (right-heart catheterisation with a vasodilator challenge) is usually necessary (Table 4) . Further investigations are shown in Table 5 .
In Sheffield 'one-stop' and 'two-stop' assessment services are offered. Many patients prefer the 'two-stop' service which allows them to meet the team prior to admission for invasive investigation.
Two-stop assessment
A number of non-invasive investigations are carried out on the initial visit of the 'two-stop' assessment. Following this, patients are usually well informed and able to consider the potential implications of a diagnosis of PH. Supplementary imaging investigations and cardiac catheterisation are performed during their second visit. Investigation results are then reviewed by a multidisciplinary team, usually allowing a clear pulmonary vascular diagnosis.
Screening
There is a 10-20% prevalence of PH in systemic sclerosis. We have identified patients with early disease (Fig 1) using a pragmatic screening approach. Patients at risk of CTEPH can be identified using the criteria in Table 6 . Family members of patients with IPH at increased risk of developing PH may be identified with the aid of genetic screening or exercise testing, although the low penetrance (10-20%) of the familial form of PH (autosomal dominant inheritance) means that this must be approached sensitively. Genetic linkage studies have mapped a disease locus, designated PPH1, to the long arm of chromosome 2; subsequently, germline mutations in the bone morphogenetic protein receptor have been identified in a subset of families with IPH. 
CME Respiratory Medicine Treatment
Treatment should ideally be instituted in a specialist centre, a view shared by patient groups (eg the Pulmonary Hypertension Association (PHA-UK)). There are five nationally designated centres in the UK (Sheffield, London, Cambridge, Newcastle and Glasgow) and a centre in Ireland; they have experience with the initiation, continued use and monitoring of targeted drug treatments and the infrastructure necessary for patient education and support. They also have expertise in patient selection for, and the timing of, surgical interventions.
Treatment is demanding but often rewarding. The right ventricle has a huge potential to remodel if pulmonary vascular resistance can be reduced by surgery or medical therapy. This is illustrated in Figs 2 and 3 which demonstrate improvement in both ECG and CXR following one year's treatment with intravenous iloprost.
Standard supportive treatments for PH include warfarin, diuretics, digoxin and oxygen therapy.
Targeted pulmonary vascular treatment
The number of targeted pulmonary vascular therapies for PAH has increased dramatically over the past five years following a number of phase 3 randomised controlled trials (RCT). These treatments are directed at the pulmonary arterial vascular bed and have also been extensively used off-label in other categories of the disease, including CTEPH. The drugs include epoprostenol (prostacyclin) and its analogues, iloprost and treprostinil, and the endothelin antagonist bosentan. These therapies are expensive, costing £20,000-35,000 per patient-year. More recently, in a few small studies the phosphodiesterase inhibitor sildenafil has reduced pulmonary artery pressure; it is currently the focus of a phase 3 multicentre study.
Complex treatments
Intravenous epoprostenol improves life expectancy, haemodynamics, six-minute walk time (frequently used as a surrogate marker of mortality) and quality of life in patients with severe IPH (New York Heart Association (NYHA) class III and IV). 4 However, continuous infusion via a Hickman line is required, posing a risk of life-threatening infection.
Iloprost is a more stable analogue of epoprostenol. It can be delivered via a Hickman line or a nebuliser. Using the latter, it was an effective treatment for PAH in the context of a multicentre RCT. 5 However, its short half-life means that patients need to nebulise 6-9 times per day.
Treprostinil, another prostaglandin analogue, administered subcutaneously, has also been shown to be efficacious in the largest RCT ever conducted in PH. 6 Problems include infusion site pain.
Oral treatments
Oral treatment options include calciumchannel antagonists. Despite a lack of RCT data they are advocated as an effective therapy, although in practice their efficacy is limited to a small minority of patients with IPH with a positive 'vasodilator response' (a fall of greater than 20% in mean pulmonary artery pressure following administration of a pulmonary vasodilator such as nitric oxide or epoprostenol). Beraprost, an orally active prostaglandin, is effective although it has been investigated only in patients with milder disease (NYHA class II and III). 7 The endothelin receptor antagonist bosentan currently represents the only licensed oral treatment for PAH in the UK. It improves the symptoms of PH and physiological markers of disease severity. 8 The results of a phase 3 study examining the potential role of sildenafil are eagerly awaited. It is anticipated that in the future patients will receive combination therapy -a number of reports suggest that combination therapy may be efficacious.
Surgical options
Patients identified as having thromboembolic disease should be assessed for pulmonary endarterectomy, which offers a return to an almost normal quality and quantity of life in a proportion of these patients. The operative mortality in experienced hands is 5-10%, comparing favourably with a five-year survival of less than 10% once a mean pulmonary artery pressure of above 50 mmHg is exceeded in this form of PH.
Heart-lung or lung transplantation is usually reserved for patients deteriorating on pulmonary vascular directed therapy.
Another option is atrial septostomy which involves making a small incision in the interatrial septum. This can be performed at cardiac catheterisation and appears to be an effective way of offloading the right ventricle, although its role is as yet not clearly defined.
Conclusions
The diagnosis of PH is often made at a mid to late stage in the course of the disease. In a study carried out by PHA-UK fewer than 5% of patients present as an acute emergency. Only 30% of patients go to see their general practitioner within one month of experiencing symptoms, most waiting over six months. Over 40% of patients go on to see four or more doctors before a diagnosis of PH is made.
With the advent of effective therapies and an increased awareness of PH, it is hoped that early diagnosis and timely referral to one of the UK specialist centres will improve the prognosis and quality of life for these patients.
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In This fear of missing PE may account for physicians being better at excluding PE (wrong in only 10% of cases) than in diagnosing it (wrong in 30% of cases) on clinical grounds. 2 In all major studies of suspected PE, it is excluded in 65-85% of cases. Unfortunately, these studies rarely discuss the nature of the true non-PE diagnosis and whether this could have been ascertained earlier; this could be a fruitful and revealing local audit project. 3 
Symptoms in pulmonary embolism and other acute chest illnesses
The commonest alternative diagnoses are shown in Table 1 . The table demonstrates how assessing presenting symptom(s) in the light of chest anatomy can focus thinking towards the probable diagnosis. PE is a disease of the pulmonary circulation, hence indirectly affecting the lung parenchyma, whereas symptoms such as cough and haemoptysis may instead arise from the airways. Junior doctors often assume that noncardiac chest pain might be due to PE, unaware that the lung has no pain fibres. PE can cause chest pain only if there are peripheral parenchymal changes spreading outside the lung to the (very sensitive) parietal pleura. Where chest radiograph (CXR) shows normal lung parenchyma, acute pleuritic chest pain most likely arises from the parietal pleura (perhaps with an effusion) or chest wall, making PE unlikely.
Dyspnoea, tachypnoea and hypoxia are 
